Skip to main content
OpenTrials

Clinical trial condition

Bronchial Neoplasms

Explore clinical trials studying Bronchial Neoplasms. Study availability and eligibility vary by location and protocol.

5,282 public trials 1,196 recruiting studies
Refine in advanced search Browse all conditions

Bronchial Neoplasms trial results

Completed

A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung

NCT02185690

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +11 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Juravinski Cancer Centre Hamilton, Ontario, Canada
  • The Ottawa Hospital Regional Cancer Centre Ottawa, Ontario, Canada
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
View Trial Details
Completed

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

NCT03708328

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +35 more
Locations
  • Columbia Univ Med Ctr New York, United States
  • MD Anderson Cancer Center Houston, Texas, United States
  • Herlev Hospital Herlev, Denmark
  • Rigshospitalet København Ø, Denmark
View all 17 locations
View Trial Details
Completed

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696

Conditions
Adnexal Diseases, Bladder Cancer, Breast Cancer, +68 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of Southern California Los Angeles, California, United States
  • Stanford Health Care Stanford, California, United States
  • Yale University Cancer Center New Haven, Connecticut, United States
View all 13 locations
View Trial Details
Completed

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

NCT03976375

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 1604) Bakersfield, California, United States
  • Cancer Specialists of North Florida - Fleming Island ( Site 1675) Fleming Island, Florida, United States
  • Mid-Florida Cancer Centers ( Site 1611) Orange City, Florida, United States
  • University of Kentucky School of Medicine & Hospitals ( Site 1621) Lexington, Kentucky, United States
View all 143 locations
View Trial Details
Completed

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

NCT04725188

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Cedars-Sinai Medical Center ( Site 2522) Los Angeles, California, United States
  • Illinois Cancer Care ( Site 2534) Peoria, Illinois, United States
  • Baptist Health Lexington-Research ( Site 2502) Lexington, Kentucky, United States
  • University of Maryland ( Site 2528) Baltimore, Maryland, United States
View all 95 locations
View Trial Details
Completed

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

NCT03126110

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +82 more
Locations
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • University of Florida Gainesville, Florida, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Washington University - Siteman Cancer Center St Louis, Missouri, United States
View all 38 locations
View Trial Details

Related conditions